RxDoctor Payments Data

Elio Novoa, MD

Internal Medicine · Jupiter, FLNPI 1124012448

Payments from drug & device makers

$1,201in general payments, 2019–2025

Across 79 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$270
  • Pfizer$202
  • Novo Nordisk$167
  • Kvk-tech, Inc.$137
  • Amarin Pharma, Inc.$136
  • AstraZeneca$53
  • plus $235 from 14 others

What the payments were for

  • Consulting fees$111%
  • Food & beverage$1,17598%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,201 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$171,686
Medicare patients
515
Services billed
2,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$107,566
JardianceEmpagliflozin34$45,177
OzempicSemaglutide30$37,049
FarxigaDapagliflozin Propanediol24$31,867
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$28,446
EntrestoSacubitril/Valsartan17$23,624
JanuviaSitagliptin Phosphate15$22,898
MounjaroTirzepatide20$21,057
TrulicityDulaglutide15$13,762
Repatha SureclickEvolocumab18$13,710
VascepaIcosapent Ethyl19$9,231
TradjentaLinagliptin12$8,313
MyrbetriqMirabegron18$7,930
Rosuvastatin Calcium419$4,848
Levothyroxine Sodium369$4,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$107,566114 claims
Boehringer IngelheimJardiance, Tradjenta$20$53,49046 claims
Novo NordiskOzempic$167$37,04930 claims
AstraZenecaFarxiga, Symbicort$53$35,60637 claims
GSKTrelegy Ellipta$13$28,44633 claims
NovartisEntresto$12$23,62417 claims
Astellas Pharma US IncMyrbetriq$11$7,93018 claims
AbbVieSynthroid$270$1,94919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →